Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Neutral to Buy with a price target of $36.00.Analyst Chris James is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE